Molecular pathogenesis of head and neck cancers

Journal of Surgical Oncology

Volumn 97, Issue 8, 2008, Pages 634-639

  Singh, Bhuvanesh ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cancer pathogenesis; Head and neck neoplasms; Molecular biology

Indexed keywords

ACETALDEHYDE; ALCOHOL; ANTINEOPLASTIC AGENT; BETA CAROTENE; CARCINOGEN; CETUXIMAB; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 2B; DNA; GEFITINIB; PANITUMUMAB; PROTEIN P21; RETINOIC ACID; RETINOL; TRACEVA; TRANSCRIPTION FACTOR E2F; VIRUS PROTEIN; WART VIRUS VACCINE; ZALUTUMUMAB;

AEROSOL; ALCOHOL CONSUMPTION; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CHROMOSOME ABERRATION; CLINICAL TRIAL; ENVIRONMENTAL EXPOSURE; ESOPHAGUS CANCER; GENETIC ASSOCIATION; HEAD AND NECK CANCER; HEREDITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL CARCINOMA; TOBACCO; TUMOR GROWTH; UTERINE CERVIX TUMOR; VIRUS INFECTION; WART VIRUS;

ALCOHOL DRINKING; ANTINEOPLASTIC AGENTS; HEAD AND NECK NEOPLASMS; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMOKING; SMOKING CESSATION; TUMOR VIRUS INFECTIONS;

EID: 44949120769     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21024     Document Type: Review

References (86)

1. Garden AS, Morrison WH, Rosenthal DI, et al.: Target coverage for head and neck cancers treated with IMRT: Review of clinical experiences. Semin Radiat Oncol 2004;14:103-109.
2. Forastiere AA, Goepfert H, Maor M, et al.: Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349:2091-2098.
3. Pirkle JL, Bernert JT, Caudill SP, et al.: Trends in the exposure of nonsmokers in the U.S. population to secondhand smoke: 1988-2002. Environ Health Perspect 2006;114:853-858.
4. Centers for Disease Control and Prevention (CDC). Annual smoking-attributable mortality, years of potential life lost, and productivity losses - United States, 1997-2001 MMWR Morb Mortal Wkly Rep 2005;54:625-628.
5. Deutsch-Wenzel RP, Brune H, Grimmer G: Experimental studies on the carcinogenicity of five nitrogen containing polycyclic aromatic compounds directly injected into rat lungs. Cancer Lett 1983;20:97-101.
6. Ho T, Wei Q, Sturgis EM: Epidemiology of carcinogen metabolism genes and risk of squamous cell carcinoma of the head and neck. Head Neck 2007;29:682-699.
7. Anantharaman D, Chaubal PM, Kannan S, et al.: Susceptibility to oral cancer by genetic polymorphisms at CYP1A1, GSTM1 and GSTT1 loci among Indians: Tobacco exposure as a risk modulator. Carcinogenesis 2007;28:1455-1462.
8. Seitz HK, Becker P: Alcohol metabolism and cancer risk. Alcohol Res Health 2007;30:38-41, 44-47.
9. Pelucchi C, Gallus S, Garavello W, et al.: Cancer risk associated with alcohol and tobacco use: Focus on upper aero-digestive tract and liver. Alcohol Res Health 2006;29:193-198.
10. Yokoyama A, Omori T: Genetic polymorphisms of alcohol and aldehyde dehydrogenases and risk for esophageal and head and neck cancers. Jpn J Clin Oncol 2003;33:111-121.
11. Lewis SJ, Smith GD: Alcohol, ALDH2, and esophageal cancer: A meta-analysis which illustrates the potentials and limitations of a Mendelian randomization approach. Cancer Epidemiol Biomarkers Prev 2005;14:1967-1971.
12. Sturgis EM, Cinciripini PM: Trends in head and neck cancer incidence in relation to smoking prevalence: An emerging epidemic of human papillomavirus-associated cancers? Cancer 2007;110:1429-1435.
13. Steben M, Duarte-Franco E: Human papillomavirus infection: Epidemiology and pathophysiology. Gynecol Oncol 2007;107:52-55.
14. Hebner CM, Laimins LA: Human papillomaviruses: Basic mechanisms of pathogenesis and oncogenicity. Rev Med Virol 2006;16:83-97.
15. Narisawa-Saito M, Kiyono T: Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: Roles of E6 and E7 proteins. Cancer Sci 2007;98:1505-1511.
16. Wreesmann VB, Singh B: Chromosomal aberrations in squamous cell carcinomas of the upper aerodigestive tract: Biologic insights and clinical opportunities. J Oral Pathol Med 2005;34:449-459.
17. Singh B, Wreesmann VB, Pfister D, et al.: Chromosomal aberrations in patients with head and neck squamous cell carcinoma do not vary based on severity of tobacco/alcohol exposure. BMC Genet 2002;3:22.
18. Koch WM, Lango M, Sewell D, et al.: Head and neck cancer in nonsmokers: A distinct clinical and molecular entity. Laryngoscope 1999;109:1544-1551.
19. Lydiatt WM, Davidson BJ, Shah J, et al.: The relationship of loss of heterozygosity to tobacco exposure and early recurrence in head and neck squamous cell carcinoma. Am J Surg 1994;168:437-440.
20. Davidson BJ, Lydiatt WM, Abate MP, et al.: Cyclin D1 abnormalities and tobacco exposure in head and neck squamous cell carcinoma. Head Neck 1996;18:512-521.
21. O'Regan EM, Toner ME, Smyth PC, et al.: Distinct array comparative genomic hybridization profiles in oral squamous cell carcinoma occurring in young patients. Head Neck 2006;28:330-338.
22. Pan H, Califano J, Ponte JF, et al.: Loss of heterozygosity patterns provide fingerprints for genetic heterogeneity in multistep cancer progression of tobacco smoke-induced non-small cell lung cancer. Cancer Res 2005;65:1664-1669.
23. Russo AL, Thiagalingam A, Pan H, et al.: Differential DNA hypermethylation of critical genes mediates the stage-specific tobacco smoke-induced neoplastic progression of lung cancer. Clin Cancer Res 2005;11:2466-2470.
24. Kraunz KS, McClean MD, Nelson HH, et al.: Duration but not intensity of alcohol and tobacco exposure predicts p16INK4A homozygous deletion in head and neck squamous cell carcinoma. Cancer Res 2006;66:4512-4515.
25. Brennan JA, Boyle JO, Koch WM, et al.: Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med 1995;332:712-717.
26. Califano J, van der Riet P, Westra W, et al.: Genetic progression model for head and neck cancer: Implications for field cancerization. Cancer Res 1996;56:2488-2492.
27. Schantz SP, Huang Q, Shah K, et al.: Mutagen sensitivity and environmental exposures as contributing causes of chromosome 3p losses in head and neck cancers. Carcinogenesis 2000;21:1239-1246.
28. Kuroki T, Trapasso F, Yendamuri S, et al.: Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma. Cancer Res 2003;63:3724-3728.
29. Wreesmann VB, Shi W, Thaler HT, et al.: Identification of novel prognosticators of outcome in squamous cell carcinoma of the head and neck. J ClinOncol 2004;22:3965-3972.
30. Singh B, Gogineni SK, Sacks PG, et al.: Molecular cytogenetic characterization of head and neck squamous cell carcinoma and refinement of 3q amplification. Cancer Res 2001;61:4506-4513.
31. Tashiro E, Tsuchiya A, Imoto M: Functions of cyclin D1 as an oncogene and regulation of cyclin D1 expression. Cancer Sci 2007;98:629-635.
32. Bova RJ, Quinn DI, Nankervis JS, et al.: Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue. Clin Cancer Res 1999;5:2810-2819.
33. Singh B, Stoffel A, Gogineni S, et al.: Amplification of the 3q26.3 locus is associated with progression to invasive cancer and is a negative prognostic factor in head and neck squamous cell carcinomas. Am J Pathol 2002;161:365-371.
34. Estilo CL, O-Charoenrat P, Ngai I, et al.: The role of novel oncogenes squamous cell carcinoma-related oncogene and phosphatidylinositol 3-kinase p110alpha in squamous cell carcinoma of the oral tongue. Clin Cancer Res 2003;9:2300-2306.
35. Sarkaria I, O-Charoenrat P, Talbot SG, et al.: Squamous cell carcinoma related oncogene/DCUN1D1 is highly conserved and activated by amplification in squamous cell carcinomas. Cancer Res 2006;66:9437-9444.
36. Ma YY, Wei SJ, Lin YC, et al.: PIK3CA as an oncogene in cervical cancer. Oncogene 2000;19:2739-2744.
37. Shayesteh L, Lu Y, Kuo WL, et al.: PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999;21:64-65.
38. Singh B, Reddy PG, Goberdhan A, et al.: p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. Genes Dev 2002;16:984-993.
39. D'Souza G, Kreimer AR, Viscidi R, et al.: Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007;356:1944-1956.
40. Fakhry C, Gillison ML: Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol 2006;24:2606-2611.
41. Gillison ML, Koch WM, Capone RB, et al.: Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000;92:709-720.
42. Kreimer AR, Clifford GM, Boyle P, et al.: Human papillomavirus types in head and neck squamous cell carcinomas worldwide: A systematic review. Cancer Epidemiol Biomarkers Prev 2005;14:467-475.
43. Kutler DI, Wreesmann VB, Goberdhan A, et al.: Human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia patients. J Natl Cancer Inst 2003;95:1718-1721.
44. Perrone F, Suardi S, Pastore E, et al: Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma. Clin Cancer Res 2006;12:6643-6651.
45. Ragin CC, Taioli E, Weissfeld JL, et al.: 11q13 amplification status and human papillomavirus in relation to p16 expression defines two distinct etiologies of head and neck tumours. Br J Cancer 2006;95:1432-1438.
46. Smeets SJ, Braakhuis BJ, Abbas S, et al.: Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. Oncogene 2006;25:2558-2564.
47. Strati K, Pitot HC, Lambert PF: Identification of biomarkers that distinguish human papillomavirus (HPV)-positive versus HPV-negative head and neck cancers in a mouse model. Proc Natl Acad Sci USA 2006;103:14152-14157.
48. Weinberger P, Kountourakis P, Sasaki C, et al.: Oropharyngeal squamous cell cancers (OSCC) bearing transcriptionally active human papillomavirus (HPV) display distinct protein expression profile. 2006 ASCO Annual Meeting Proceedings. J Clin Oncol 2006;24:10028.
49. Weinberger PM, Yu Z, Haffty BG, et al.: Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 2006;24:736-747.
50. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000;100:57-70.
51. Karamouzis MV, Grandis JR, Argiris A: Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA 2007;298:70-82.
52. Kalyankrishna S, Grandis JR: Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 2006;24:2666-2672.
53. Fisher MJ, Virmani AK, Wu L, et al.: Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer. Clin Cancer Res 2001;7:1688-1697.
54. Pai SI, Wu GS, Ozoren N, et al.: Rare loss-of-function mutation of a death receptor gene in head and neck cancer. Cancer Res 1998;58:3513-3518.
55. Mandruzzato S, Brasseur F, Andry G, et al.: A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J Exp Med 1997;186:785-793.
56. Campisi JJ, d'Adda di Fagagna FF: Cellular senescence: When bad things happen to good cells. Nat Rev Mol Cell Biol 2007;8:729-740.
57. Gilson E, Géli V: How telomeres are replicated. Nat Rev Mol Cell Biol 2007;8:825-838.
58. Soder AI, Hoare SF, Muir S, et al.: Amplification, increased dosage and in situ expression of the telomerase RNA gene in human cancer. Oncogene 1997;14:1013-1021.
59. Gordon KE, Ireland H, Roberts M, et al.: High levels of telomere dysfunction bestow a selective disadvantage during the progression of human oral squamous cell carcinoma. Cancer Res 2003;63:458-467.
60. Gordon KE, Parkinson EK: Analysis of telomerase activity and telomere function in cancer. Methods Mol Biol 2004;281:333-348.
61. Folkman J: Angiogenesis. Annu Rev Med 2006;57:1-18.
62. Johnstone S, Logan RM: The role of vascular endothelial growth factor (VEGF) in oral dysplasia and oral squamous cell carcinoma. Oral Oncol 2006;42:337-342.
63. Friedl P, Wolf K: Tumour-cell invasion and migration: Diversity and escape mechanisms. Nat Rev Cancer 2003;3:362-374.
64. Thomas GJ, Speight PM: Cell adhesion molecules and oral cancer. Crit Rev Oral Biol Med 2001;12:479-498.
65. Werner JA, Rathcke IO, Mandic R: The role of matrix metalloproteinases in squamous cell carcinomas of the head and neck. Clin Exp Metastasis 2002;19:275-282.
66. Howell GM, Grandis JR: Molecular mediators of metastasis in head and neck squamous cell carcinoma. Head Neck 2005;27:710-717.
67. O-Charoenrat P, Rhys-Evans PH, Eccles SA: Expression of matrix metalloproteinases and their inhibitors correlates with invasion and metastasis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2001;127:813-820.
68. Rogers SJ, Harrington KJ, Rhys-Evans P, et al.: Biological significance of c-erbB family oncogenes in head and neck cancer. Cancer Metastasis Rev 2005;24:47-69.
69. Wrangle JM, Khuri FR: Chemoprevention of squamous cell carcinoma of the head and neck. Curr Opin Oncol 2007;19:180-187.
70. Jiménez P, García A, Santander S, et al.: Prevention of cancer in the upper gastrointestinal tract with COX-inhibition. Still an option? CurPharma Des 2007;13:2261-2273.
71. Saba NF, Hammond A, Shin DM, et al.: Moving toward bioadjuvant approaches to head and neck cancer prevention. Int J Radiat Oncol Biol Phys 2007;69:5132-5135.
72. Centers for Disease Control and Prevention (CDC): Tobacco use among adults - United States, 2005 MMWR Morb Mortal Wkly Rep 2006;55:1145-1148.
73. Browman GP, Wong G, Hodson I, et al.: Influence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer. N Engl J Med 1993;328:159-163.
74. Khuri FR, Kim ES, Lee JJ, et al.: The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. Cancer Epidemiol Biomarkers Prev 2001;10:823-829.
75. Day GL, Blot WJ, Shore RE, et al.: Second cancers following oral and pharyngeal cancers: Role of tobacco and alcohol. J Natl Cancer Inst 1994;86:131-137.
76. Fisher EB, Jr., Haire-Joshu D, Morgan GD, et al.: Smoking and smoking cessation. Am Rev Respir Dis 1990;142:702-720.
77. Fisher EB, Jr., Lichtenstein E, Haire-Joshu D, et al.: Methods, successes, and failures of smoking cessation programs. Annu Rev Med 1993;44:481-513.
78. Pike KJ, Rabius V, McAlister A, et al.: American Cancer Society's QuitLink: Randomized trial of Internet assistance. Nicotine Tob Res 2007;9:415-420.
79. Garland SM, Hernandez-Avila M, Wheeler CM, et al.: Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-1943.
80. Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-1927.
81. Joura EA, Leodolter S, Hernandez-Avila M, et al.: Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: A combined analysis of three randomised clinical trials. Lancet 2007;369:1693-1702.
82. Paavonen J, Jenkins D, Bosch FX, et al.: Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369:2135-2137.
83. Stanley M: Prevention strategies against the human papillomavirus: The effectiveness of vaccination. Gynecol Oncol 2007;107:S19-S23.
84. Bonner JA, Harari PM, Giralt J, et al.: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-578.
85. Vermorken J, Mesia R, Vega V, et al.: Cetuximab extends survival of patients with recurrent or metastatic SCCHN when added to first line platinum based therapy - Results of a randomized phase III (Extreme) study. In: 2007 ASCO Annual Meeting. 2007.
86. Pfister DG, Su YB, Kraus DH, et al.: Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: A pilot phase II study of a new combined-modality paradigm. J Clin Oncol 2006;24:1072-1078.